GNFT
Genfit
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as nash - nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). genfit is committed to contribute to bringing new medicines to market for patients who lack suitable solutions, and strives to implement mutually beneficial approaches that combine novel drugs and biomarkers. its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including genfit’s lead proprietary compound, gft505, that is completing a phase 2b study in nash.
Market Cap: 177 Million
Primary Exchange: NASDAQ
Website: https://www.genfit.fr/
Shares Outstanding: 49.8 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 1767 trading days
From: 2019-04-08 To: 2024-03-07
Lowest Point:
Akero Therapeutics Readies $75 Million IPO
via: SeekingAlpha at 2019-06-13 09:11:26:000
Quick Take Akero Therapeutics ( AKRO ) has filed to raise gross proceeds of $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing a treatment for metabolic diseases with high unmet clinical needs, with an initial focus on non-alcoholic steato… read more...
Merck And Private Partner NGM Hope For Once-Monthly Dosing NASH Drug
via: SeekingAlpha at 2019-06-11 15:33:43:000
Merck (MRK) and its partner NGM Biopharmaceuticals hope to deliver on a potential treatment for non-alcoholic steatohepatitis and type 2 diabetes. This is what both companies showed when some preliminary data was released for a study using MK-3655 to treat patients with non-alcoholic fatty l… read more...
Merck And Private Partner NGM Hope For Once-Monthly Dosing NASH Drug
via: SeekingAlpha at 2019-06-11 15:33:43:000
Merck (MRK) and its partner NGM Biopharmaceuticals hope to deliver on a potential treatment for non-alcoholic steatohepatitis and type 2 diabetes. This is what both companies showed when some preliminary data was released for a study using MK-3655 to treat patients with non-alcoholic fatty l… read more...
Genfit defends elafibranor after CymaBay-linked selloff; shares off 14%
via: SeekingAlpha at 2019-06-11 10:08:42:000
In the wake of a selloff stoked by disappointing results for CymaBay's NASH candidate seladelpar, Genfit SA ( GNFT -14.2% ) has released a letter to investors aimed at clearing up any "confusion" with elafibranor. To wit: More news on: Genfit SA, Healthcare stocks news, Stocks on the… read more...
Genfit defends elafibranor after CymaBay-linked selloff; shares off 14%
via: SeekingAlpha at 2019-06-11 10:08:42:000
In the wake of a selloff stoked by disappointing results for CymaBay's NASH candidate seladelpar, Genfit SA ( GNFT -14.2% ) has released a letter to investors aimed at clearing up any "confusion" with elafibranor. To wit: More news on: Genfit SA, Healthcare stocks news, Stocks on the… read more...
Healthcare tops midday movers
via: SeekingAlpha at 2019-06-11 08:41:05:000
Gainers: Jaguar Health (NASDAQ: JAGX ) +60% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +40% . TORM (NASDAQ: TRMD ) +20% . Rekor Systems, Inc. (REKR) +17% . Enzo Biochem, Inc. (NYSE: ENZ ) +17% . Oxbridge Re Holdings (NASDAQ: OXBR ) +16% . Tenax Therapeutics (NASDAQ: TENX ) +1… read more...
Healthcare tops midday movers
via: SeekingAlpha at 2019-06-11 08:41:05:000
Gainers: Jaguar Health (NASDAQ: JAGX ) +60% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +40% . TORM (NASDAQ: TRMD ) +20% . Rekor Systems, Inc. (REKR) +17% . Enzo Biochem, Inc. (NYSE: ENZ ) +17% . Oxbridge Re Holdings (NASDAQ: OXBR ) +16% . Tenax Therapeutics (NASDAQ: TENX ) +1… read more...
CymaBay downdraft snares Genfit, down 13%
via: SeekingAlpha at 2019-06-11 05:58:35:000
The seladelpar-stoked selloff in CymaBay Therapeutics has engulfed fellow NASH player Genfit SA ( GNFT -13.3% ). More news on: Genfit SA, Healthcare stocks news, Stocks on the move, Read more … read more...
CymaBay downdraft snares Genfit, down 13%
via: SeekingAlpha at 2019-06-11 05:58:35:000
The seladelpar-stoked selloff in CymaBay Therapeutics has engulfed fellow NASH player Genfit SA ( GNFT -13.3% ). More news on: Genfit SA, Healthcare stocks news, Stocks on the move, Read more … read more...
HDS, SYMC and BYND among premarket losers
via: SeekingAlpha at 2019-06-11 05:16:59:000
CymaBay Therapeutics (NASDAQ: CBAY ) -45% on disappointing data on NASH candidate seladelpar. More news on: CymaBay Therapeutics, Inc., Achieve Life Sciences, Inc., Beyond Meat, Inc., Stocks on the move, Read more … read more...
HDS, SYMC and BYND among premarket losers
via: SeekingAlpha at 2019-06-11 05:16:59:000
CymaBay Therapeutics (NASDAQ: CBAY ) -45% on disappointing data on NASH candidate seladelpar. More news on: CymaBay Therapeutics, Inc., Achieve Life Sciences, Inc., Beyond Meat, Inc., Stocks on the move, Read more … read more...
A Closer Look: Genfit's Prospects In NASH
via: SeekingAlpha at 2019-06-10 08:26:04:000
Introduction Much has been made of the NASH race, which came to a pinnacle of hype in 2018 with stocks like Madrigal ( MDGL ) & Viking ( VKTX ) quadrupling in value. The mood has since subdued, as the realization of competition and the hurdles to market have set in. Genfit ( OTCPK:GNF… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|